Bukwang Pharmaceutical Co., Ltd. (KRX:003000)
South Korea · Delayed Price · Currency is KRW 3,840.00
+155.00 (4.21%)
Nov 4, 2026, 3:30 PM KST
Bukwang Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 378,872 | 373,446 | 314,207 | 417,573 | 598,978 | 883,065 | |
Market Cap Growth | 3.92% | 18.85% | -24.75% | -30.29% | -32.17% | -54.11% |
Enterprise Value | 290,702 | 236,540 | 280,401 | 368,683 | 519,044 | 826,852 |
Last Close Price | 3840.00 | 3785.00 | 4109.78 | 5461.80 | 7834.55 | 11550.36 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 42.88 | 29.74 | - | - | - | - |
Forward PE | - | 58.75 | 58.75 | 58.75 | 58.75 | 58.75 |
PS Ratio | 1.76 | 1.86 | 1.96 | 3.32 | 3.14 | 4.84 |
PB Ratio | 1.13 | 1.10 | 1.29 | 1.78 | 2.20 | 3.15 |
P/TBV Ratio | 1.16 | 1.11 | 1.32 | 1.93 | 2.34 | 3.36 |
P/FCF Ratio | - | 26.29 | 9.69 | - | 49.25 | 34.31 |
P/OCF Ratio | 69.16 | 17.40 | 9.14 | - | 36.39 | 33.29 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.35 | 1.18 | 1.75 | 2.93 | 2.72 | 4.53 |
EV/EBITDA Ratio | 17.35 | 12.04 | 48.99 | - | 106.23 | 79.01 |
EV/EBIT Ratio | 24.96 | 16.70 | 173.34 | - | - | 147.08 |
EV/FCF Ratio | - | 16.65 | 8.65 | - | 42.67 | 32.12 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.24 | 0.24 | 0.33 | 0.34 | 0.00 | 0.01 |
Debt / EBITDA Ratio | 4.81 | 4.09 | 13.88 | - | 0.19 | 0.15 |
Debt / FCF Ratio | - | 5.66 | 2.45 | - | 0.08 | 0.06 |
Net Debt / Equity Ratio | -0.26 | -0.40 | -0.21 | -0.31 | -0.31 | -0.29 |
Net Debt / EBITDA Ratio | -5.28 | -6.91 | -8.85 | 2.16 | -17.31 | -7.90 |
Net Debt / FCF Ratio | 57.59 | -9.56 | -1.56 | 5.89 | -6.95 | -3.21 |
Asset Turnover | 0.51 | 0.47 | 0.40 | 0.30 | 0.48 | 0.46 |
Inventory Turnover | 2.36 | 2.33 | 1.75 | 1.66 | 2.87 | 2.36 |
Quick Ratio | 1.79 | 2.09 | 4.37 | 1.93 | 3.90 | 4.79 |
Current Ratio | 2.33 | 2.57 | 5.76 | 2.61 | 4.90 | 5.95 |
Return on Equity (ROE) | 2.97% | 4.25% | -1.45% | -13.60% | -1.54% | -1.01% |
Return on Assets (ROA) | 1.71% | 2.08% | 0.25% | -5.65% | -0.04% | 0.88% |
Return on Invested Capital (ROIC) | 5.17% | 7.11% | 0.91% | -21.45% | -0.12% | -2.07% |
Return on Capital Employed (ROCE) | 3.30% | 4.00% | 0.50% | -11.30% | -0.10% | 1.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.33% | 3.36% | -0.84% | -7.50% | -0.41% | -0.10% |
FCF Yield | -0.41% | 3.80% | 10.32% | -2.92% | 2.03% | 2.92% |
Dividend Yield | 3.91% | 3.30% | - | - | - | - |
Payout Ratio | 140.49% | 39.28% | - | - | - | - |
Buyback Yield / Dilution | -38.04% | -20.67% | - | - | 0.01% | 0.25% |
Total Shareholder Return | -34.14% | -17.37% | - | - | 0.01% | 0.25% |